Pruritus - Pipeline Review, H2 2017

Published: Aug, 2017 | Pages: 131 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pruritus - Pipeline Review, H2 2017, provides an overview of the Pruritus (Dermatology) pipeline landscape.

Pruritus, or itch, is defined as an unpleasant sensation that provokes the desire to scratch. Pruritus is caused by cancer, cancer treatments, infection, dry skin and reaction to a drug. Symptoms include redness, bumps, spots or blisters, dry, cracked skin and leathery or scaly texture to the skin. Risk factors include heat, allergic, asthma, hay fever, hives and eczema. Treatment includes corticosteroids, antihistamines and antidepressants.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pruritus - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Pruritus (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pruritus (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Pruritus and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 4, 12, 6, 1 and 8 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively.

Pruritus (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Pruritus (Dermatology).
- The pipeline guide reviews pipeline therapeutics for Pruritus (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Pruritus (Dermatology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Pruritus (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Pruritus (Dermatology)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Pruritus (Dermatology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Pruritus (Dermatology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents
 2
List of Tables 4
List of Figures 4
Introduction 6
Global Markets Direct Report Coverage 6
Pruritus - Overview 7
Pruritus - Therapeutics Development 8
Pipeline Overview 8
Pipeline by Companies 9
Pipeline by Universities/Institutes 12
Products under Development by Companies 13
Products under Development by Universities/Institutes 15
Pruritus - Therapeutics Assessment 16
Assessment by Target 16
Assessment by Mechanism of Action 19
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Pruritus - Companies Involved in Therapeutics Development 26
Albireo Pharma Inc 26
Allergan Plc 26
Amorepacific Corp 27
Asana BioSciences LLC 27
Cara Therapeutics Inc 28
Celgene Corp 28
Chugai Pharmaceutical Co Ltd 29
ELORAC Inc 29
GlaxoSmithKline Plc 30
Hydra Biosciences Inc 30
J Uriach Y Compania SA 31
NeuroCycle Therapeutics GmbH 31
Patagonia Pharmaceuticals LLC 32
Patara Pharma Inc 32
Phosphagenics Ltd 33
RDD Pharma Ltd 33
Sanwa Kagaku Kenkyusho Co Ltd 34
Shionogi & Co Ltd 34
Sienna Biopharmaceuticals Inc 35
Sumitomo Dainippon Pharma Co Ltd 35
Teikoku Pharma USA Inc 36
Tesaro Inc 36
Tioga Pharmaceuticals Inc 37
Toray Industries Inc 37
Vanda Pharmaceuticals Inc 38
Pruritus - Drug Profiles 39
A-4250 - Drug Profile 39
apremilast - Drug Profile 43
asimadoline - Drug Profile 54
ASN-008 - Drug Profile 56
B-244 - Drug Profile 57
cromolyn sodium - Drug Profile 59
difelikefalin - Drug Profile 61
GSK-2330672 - Drug Profile 71
lidocaine hydrochloride - Drug Profile 73
nalbuphine hydrochloride ER - Drug Profile 74
nalfurafine hydrochloride - Drug Profile 77
naloxone hydrochloride - Drug Profile 79
NCT-10004 - Drug Profile 80
nemolizumab - Drug Profile 81
onabotulinumtoxinA - Drug Profile 83
PAC-14028 - Drug Profile 88
PATN-02 - Drug Profile 90
Peptides to Target TRPV1 for Pain and Itch - Drug Profile 91
phenylbutyrate - Drug Profile 92
PR-38 - Drug Profile 93
RDD-1609 - Drug Profile 94
rupatadine - Drug Profile 95
SCH-900978 - Drug Profile 96
serlopitant - Drug Profile 97
SK-1405 - Drug Profile 100
Small Molecule for Pruritus - Drug Profile 101
Small Molecule to Agonize KOR1 for Pruritus - Drug Profile 102
Small Molecules to Agonize CB2 for Pruritus - Drug Profile 103
Small Molecules to Antagonize Mas-Related G-Protein Coupled Receptor for Pruritus - Drug Profile 104
Small Molecules to Antagonize TRPV3 for Pain,Pruritus and Psoriasis - Drug Profile 105
SNA-120 - Drug Profile 106
SNA-125 - Drug Profile 109
TPU-010 - Drug Profile 110
tradipitant - Drug Profile 111
VVZ-149 - Drug Profile 113
Pruritus - Dormant Projects 115
Pruritus - Discontinued Products 117
Pruritus - Product Development Milestones 118
Featured News & Press Releases 118
Appendix 128
Methodology 128
Coverage 128
Secondary Research 128
Primary Research 128
Expert Panel Validation 128
Contact Us 128
Disclaimer 129

List of Tables

Number of Products under Development for Pruritus, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Pruritus - Pipeline by Albireo Pharma Inc, H2 2017
Pruritus - Pipeline by Allergan Plc, H2 2017
Pruritus - Pipeline by Amorepacific Corp, H2 2017
Pruritus - Pipeline by Asana BioSciences LLC, H2 2017
Pruritus - Pipeline by Cara Therapeutics Inc, H2 2017
Pruritus - Pipeline by Celgene Corp, H2 2017
Pruritus - Pipeline by Chugai Pharmaceutical Co Ltd, H2 2017
Pruritus - Pipeline by ELORAC Inc, H2 2017
Pruritus - Pipeline by GlaxoSmithKline Plc, H2 2017
Pruritus - Pipeline by Hydra Biosciences Inc, H2 2017
Pruritus - Pipeline by J Uriach Y Compania SA, H2 2017
Pruritus - Pipeline by NeuroCycle Therapeutics GmbH, H2 2017
Pruritus - Pipeline by Patagonia Pharmaceuticals LLC, H2 2017
Pruritus - Pipeline by Patara Pharma Inc, H2 2017
Pruritus - Pipeline by Phosphagenics Ltd, H2 2017
Pruritus - Pipeline by RDD Pharma Ltd, H2 2017
Pruritus - Pipeline by Sanwa Kagaku Kenkyusho Co Ltd, H2 2017
Pruritus - Pipeline by Shionogi & Co Ltd, H2 2017
Pruritus - Pipeline by Sienna Biopharmaceuticals Inc, H2 2017
Pruritus - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2017
Pruritus - Pipeline by Teikoku Pharma USA Inc, H2 2017
Pruritus - Pipeline by Tesaro Inc, H2 2017
Pruritus - Pipeline by Tioga Pharmaceuticals Inc, H2 2017
Pruritus - Pipeline by Toray Industries Inc, H2 2017
Pruritus - Pipeline by Vanda Pharmaceuticals Inc, H2 2017
Pruritus - Dormant Projects, H2 2017
Pruritus - Dormant Projects, H2 2017 (Contd..1), H2 2017
Pruritus - Discontinued Products, H2 2017